+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Liquid Biopsy - Global Market Trajectory & Analytics

  • ID: 4805602
  • Report
  • April 2021
  • Region: Global
  • 148 pages
  • Global Industry Analysts, Inc
Global Liquid Biopsy Market to Reach $3.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Liquid Biopsy estimated at US$1.1 Billion in the year 2020, is projected to reach a revised size of US$3.8 Billion by 2027, growing at a CAGR of 20.2% over the analysis period 2020-2027. Lung, one of the segments analyzed in the report, is projected to record a 20.5% CAGR and reach US$1.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Breast segment is readjusted to a revised 21.5% CAGR for the next 7-year period.



The U.S. Market is Estimated at $315 Million, While China is Forecast to Grow at 19.8% CAGR

The Liquid Biopsy market in the U.S. is estimated at US$315 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$672.3 Million by the year 2027 trailing a CAGR of 19.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 18.1% and 17.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 14.1% CAGR.

Colorectal Segment to Record 19.5% CAGR

In the global Colorectal segment, USA, Canada, Japan, China and Europe will drive the 19.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$144.5 Million in the year 2020 will reach a projected size of US$502.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$447.7 Million by the year 2027.

Select Competitors (Total 42 Featured):
  • Biocept, Inc.
  • Bio-Rad Laboratories, Inc.
  • Genomic Health, Inc.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • MDxHealth SA
  • Menarini Silicon Biosystems Spa
  • Myriad Genetics, Inc.
  • Qiagen NV
  • RainDance Technologies, Inc.
  • Roche Diagnostics (Schweiz) AG
  • Thermo Fisher Scientific, Inc.
  • TrovaGene, Inc.
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Table 1: World Current & Future Analysis for Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 2: World 7-Year Perspective for Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
  • Table 3: World Current & Future Analysis for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 4: World 7-Year Perspective for Lung by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 5: World Current & Future Analysis for Breast by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 6: World 7-Year Perspective for Breast by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 7: World Current & Future Analysis for Colorectal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 8: World 7-Year Perspective for Colorectal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 9: World Current & Future Analysis for Prostate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 10: World 7-Year Perspective for Prostate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 11: World Current & Future Analysis for Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 12: World 7-Year Perspective for Liver by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 13: World Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 14: World 7-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 15: World Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 16: World 7-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 17: World Current & Future Analysis for Assay Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 18: World 7-Year Perspective for Assay Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 19: World Current & Future Analysis for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 20: World 7-Year Perspective for Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
III. MARKET ANALYSIS
  • Table 21: USA Current & Future Analysis for Liquid Biopsy by Cancer Type - Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 22: USA 7-Year Perspective for Liquid Biopsy by Cancer Type - Percentage Breakdown of Value Sales for Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types for the Years 2020 & 2027
  • Table 23: USA Current & Future Analysis for Liquid Biopsy by Product - Instruments, Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 24: USA 7-Year Perspective for Liquid Biopsy by Product - Percentage Breakdown of Value Sales for Instruments, Assay Kits and Reagents for the Years 2020 & 2027
  • Table 25: Canada Current & Future Analysis for Liquid Biopsy by Cancer Type - Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 26: Canada 7-Year Perspective for Liquid Biopsy by Cancer Type - Percentage Breakdown of Value Sales for Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types for the Years 2020 & 2027
  • Table 27: Canada Current & Future Analysis for Liquid Biopsy by Product - Instruments, Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 28: Canada 7-Year Perspective for Liquid Biopsy by Product - Percentage Breakdown of Value Sales for Instruments, Assay Kits and Reagents for the Years 2020 & 2027
  • Table 29: Japan Current & Future Analysis for Liquid Biopsy by Cancer Type - Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 30: Japan 7-Year Perspective for Liquid Biopsy by Cancer Type - Percentage Breakdown of Value Sales for Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types for the Years 2020 & 2027
  • Table 31: Japan Current & Future Analysis for Liquid Biopsy by Product - Instruments, Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 32: Japan 7-Year Perspective for Liquid Biopsy by Product - Percentage Breakdown of Value Sales for Instruments, Assay Kits and Reagents for the Years 2020 & 2027
  • Table 33: China Current & Future Analysis for Liquid Biopsy by Cancer Type - Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 34: China 7-Year Perspective for Liquid Biopsy by Cancer Type - Percentage Breakdown of Value Sales for Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types for the Years 2020 & 2027
  • Table 35: China Current & Future Analysis for Liquid Biopsy by Product - Instruments, Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 36: China 7-Year Perspective for Liquid Biopsy by Product - Percentage Breakdown of Value Sales for Instruments, Assay Kits and Reagents for the Years 2020 & 2027
  • Table 37: Europe Current & Future Analysis for Liquid Biopsy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 38: Europe 7-Year Perspective for Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
  • Table 39: Europe Current & Future Analysis for Liquid Biopsy by Cancer Type - Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 40: Europe 7-Year Perspective for Liquid Biopsy by Cancer Type - Percentage Breakdown of Value Sales for Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types for the Years 2020 & 2027
  • Table 41: Europe Current & Future Analysis for Liquid Biopsy by Product - Instruments, Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 42: Europe 7-Year Perspective for Liquid Biopsy by Product - Percentage Breakdown of Value Sales for Instruments, Assay Kits and Reagents for the Years 2020 & 2027
  • Table 43: France Current & Future Analysis for Liquid Biopsy by Cancer Type - Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 44: France 7-Year Perspective for Liquid Biopsy by Cancer Type - Percentage Breakdown of Value Sales for Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types for the Years 2020 & 2027
  • Table 45: France Current & Future Analysis for Liquid Biopsy by Product - Instruments, Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 46: France 7-Year Perspective for Liquid Biopsy by Product - Percentage Breakdown of Value Sales for Instruments, Assay Kits and Reagents for the Years 2020 & 2027
  • Table 47: Germany Current & Future Analysis for Liquid Biopsy by Cancer Type - Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 48: Germany 7-Year Perspective for Liquid Biopsy by Cancer Type - Percentage Breakdown of Value Sales for Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types for the Years 2020 & 2027
  • Table 49: Germany Current & Future Analysis for Liquid Biopsy by Product - Instruments, Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 50: Germany 7-Year Perspective for Liquid Biopsy by Product - Percentage Breakdown of Value Sales for Instruments, Assay Kits and Reagents for the Years 2020 & 2027
  • Table 51: Italy Current & Future Analysis for Liquid Biopsy by Cancer Type - Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 52: Italy 7-Year Perspective for Liquid Biopsy by Cancer Type - Percentage Breakdown of Value Sales for Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types for the Years 2020 & 2027
  • Table 53: Italy Current & Future Analysis for Liquid Biopsy by Product - Instruments, Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 54: Italy 7-Year Perspective for Liquid Biopsy by Product - Percentage Breakdown of Value Sales for Instruments, Assay Kits and Reagents for the Years 2020 & 2027
  • Table 55: UK Current & Future Analysis for Liquid Biopsy by Cancer Type - Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 56: UK 7-Year Perspective for Liquid Biopsy by Cancer Type - Percentage Breakdown of Value Sales for Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types for the Years 2020 & 2027
  • Table 57: UK Current & Future Analysis for Liquid Biopsy by Product - Instruments, Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 58: UK 7-Year Perspective for Liquid Biopsy by Product - Percentage Breakdown of Value Sales for Instruments, Assay Kits and Reagents for the Years 2020 & 2027
  • Table 59: Rest of Europe Current & Future Analysis for Liquid Biopsy by Cancer Type - Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 60: Rest of Europe 7-Year Perspective for Liquid Biopsy by Cancer Type - Percentage Breakdown of Value Sales for Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types for the Years 2020 & 2027
  • Table 61: Rest of Europe Current & Future Analysis for Liquid Biopsy by Product - Instruments, Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 62: Rest of Europe 7-Year Perspective for Liquid Biopsy by Product - Percentage Breakdown of Value Sales for Instruments, Assay Kits and Reagents for the Years 2020 & 2027
  • Table 63: Asia-Pacific Current & Future Analysis for Liquid Biopsy by Cancer Type - Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 64: Asia-Pacific 7-Year Perspective for Liquid Biopsy by Cancer Type - Percentage Breakdown of Value Sales for Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types for the Years 2020 & 2027
  • Table 65: Asia-Pacific Current & Future Analysis for Liquid Biopsy by Product - Instruments, Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 66: Asia-Pacific 7-Year Perspective for Liquid Biopsy by Product - Percentage Breakdown of Value Sales for Instruments, Assay Kits and Reagents for the Years 2020 & 2027
  • Table 67: Rest of World Current & Future Analysis for Liquid Biopsy by Cancer Type - Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 68: Rest of World 7-Year Perspective for Liquid Biopsy by Cancer Type - Percentage Breakdown of Value Sales for Lung, Breast, Colorectal, Prostate, Liver and Other Cancer Types for the Years 2020 & 2027
  • Table 69: Rest of World Current & Future Analysis for Liquid Biopsy by Product - Instruments, Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 70: Rest of World 7-Year Perspective for Liquid Biopsy by Product - Percentage Breakdown of Value Sales for Instruments, Assay Kits and Reagents for the Years 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 42
Note: Product cover images may vary from those shown
Adroll
adroll